John H. Sampson, MD, PhD, MBA, MHSc, chief, Division of Neurosurgery, Duke University Medical Center, discusses results from cohort 1 of the CHECKMATE-143 trial. Sampson reported these findings at the 2015 Annual Meeting of the Society for Neuro-Oncology.

In this cohort, patients with recurrent glioblastoma were randomized to receive nivolumab in combination with ipilimumab or nivolumab alone. Nivolumab monotherapy demonstrated a superior safety profile.

Sampson added that patients treated with nivolumab monotherapy had a median overall survival of 10.5 months and 40% were alive after one year. This is encouraging, he says, because the median overall survival with bevacizumab (the current standard of care) is between seven and 10 months and the one-year survival rate is 26%.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Immuno-Oncology

Brain Cancer

 Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Society for Neuro-Oncology Annual Meeting

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma